Quantitative Assessment of Common Genetic Variants on Chromosome 5p12 and Hormone Receptor Status with Breast Cancer Risk

Yanmin Yu1,*, Zenggan Chen2,*, Hong Wang3*, Yan Zhang4*

1 Department of Breast Surgery, Huangpu Central Hospital of Shanghai, Shanghai, People’s Republic of China, 2 Department of Orthopedics, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China, 3 Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China, 4 Department of Radiology, Huangpu Central Hospital of Shanghai, Shanghai, People’s Republic of China

Abstract

Several genome-wide association studies on breast cancer (BC) have reported similar findings of a new susceptibility locus, 5p12. After that, a number of studies reported that the rs10941679, rs4415084, and rs981782 polymorphism in chromosome 5p12 has been implicated in BC risk. However, the studies have yielded contradictory results. To derive a more precise estimation of the relationship, a meta-analysis of 131,983 BC cases and 200,314 controls from 24 published case-control studies was performed. Overall, significantly elevated BC risk was associated with rs10941679, rs4415084, and rs981782 risk allele when all studies were pooled into the meta-analysis. In the subgroup analysis by ethnicity, significantly increased risks were found for the rs10941679 and rs4415084 polymorphism among Caucasians and East Asians, while no significant associations were observed for the two polymorphisms in African and other ethnic populations. For 5p12-rs981782, significant associations were only detected among Caucasians. In addition, we found that rs10941679 and rs4415084 on 5p12 confer risk, exclusively for estrogen receptor (ER)-positive tumors with per-allele OR of 1.16 (95% CI: 1.11–1.21; P<10−5) and of 1.14 (95% CI: 1.09–1.19; P<10−5) respectively. Ethnicity was identified as a potential source of between-study heterogeneity. In conclusion, this meta-analysis demonstrated that common variations are a risk factor associated with increased BC susceptibility, but these associations vary in different ethnic populations.

Introduction

Breast cancer (BC) is one of the most common malignancies among women worldwide [1]. Although life/environment related factors, such as age at menarche, menopause and first birth and exogenous hormone use are implicated in breast carcinogenesis [2,3], it is a complex polygenic disorder for which genetic factors play an important role in disease etiology [4,5]. In the past decades, high-penetrance genes (for example, BRCA1, BRCA2, PTEN and TP53) have been identified to be associated with familiar breast cancer [6]. However, these genes account for less than 5% of overall breast cancer patients and most of the risk is likely to be attributable to more low-penetrance genetic variants [7,8].

Recently, spectacular advance was made in identifying susceptible genes involved in breast cancer through genome-wide association strategy (GWAS) [9–11]. So far, genome-wide association studies (GWASs) have reported over 40 common low-penetrance variants in 25 loci that are associated with the breast cancer risk reported in the National Human Genome Research Institute catalog [12]. The most strongly and consistently associated single-nucleotide polymorphisms (SNPs) reside in intron 2 of the receptor tyrosine kinase FGFR2 (rs2981582) at 10q26.13 and near the 5’ end of the TOX3 gene at 16q12.1 (rs3803662) [13,14]. The chromosome 5p12 region has been identified as a hotspot for breast cancer susceptibility by recent genome-wide association (GWA) studies [15,16]. Three polymorphisms (rs10941679, rs4415084, and rs981782) in the region and breast cancer risk have been independently replicated by subsequent studies; however, a proportion of them have produced contrary results. These disparate findings may be due partly to insufficient power, phenotypic heterogeneity, population stratification, small effect of the polymorphism on breast cancer risk, and even publication biases. In addition, with the increased studies in recent years among Asian and African populations, there is a need to reconcile these data. We therefore performed a meta-analysis of the published studies to clarify this inconsistency and to establish a comprehensive picture of the relationship between common variants on chromosome 5p12 and breast cancer.

Materials and Methods

Literature Search Strategy and Selection Criteria

Genetic association studies published before the end of March 2013 on breast cancer and polymorphisms in the chromosome
5p12 were sought by computer-based searches from databases including MEDLINE, PubMed, EMBASE, ISI web of science and CNKI (China National Knowledge Infrastructure) without language restriction. Search term combinations were keywords relating to the chromosome 5p12 (e.g., “5p12”, “rs10941679”, “rs4415084”, “rs901782”) in combination with words related to breast cancer (e.g., breast cancer” or “malignant breast neoplasm”). We replaced one term each time until all possible combination mode were searched to avoid any missing literature. The titles and abstracts of potential articles were screened to determine their relevance, and any clearly irrelevant studies were excluded. The full texts of the remaining articles were read to determine whether they contained information on the topic of interest. Furthermore, reference lists of primary studies and review articles were also reviewed by a manual search to identify additional relevant publications.

The included studies have to meet the following criteria: (1) original papers containing independent data, (2) identification of breast cancer patients was confirmed histologically or pathologically, (3) genotype distribution information or odds ratio (OR) with its 95% confidence interval (CI) and P-value, (4) case–control or cohort studies. The major reasons for exclusion of studies were (1) overlapping data, (2) case-only studies, (3) family based studies, and review articles.

Data Extraction

Data extraction was performed independently by two reviewers and differences were resolved by further discussion among all authors. For each included study, the following information was extracted from each report according to a fixed protocol: first author, publication year, definition and numbers of cases and controls, frequency of genotypes, age, cigarette smoking, alcohol drinking, ethnicity, Hardy–Weinberg equilibrium (HWE) status, source of control, estrogen receptor (ER) status, progesterone receptor (PR) status and genotyping method. Studies with different ethnic groups were considered as individual studies for our analyses.

Statistical Methods

Deviation from HWE for controls was examined by χ² tests. OR with 95% CIs was used to assess the strength of association between the 5p12 polymorphisms and breast cancer risk. The per-allele OR of the risk allele was estimated. Then we estimated the risks of the heterozygous and homozygote genotypes on breast cancer, compared with the wild-type homozygote. Random-effects and fixed-effect summary measures were calculated as inverse-variance-weighted average of the log odds ratio. The results of random-effects summary were reported in the text because it takes into account the variation between studies. Heterogeneity across individual studies was calculated using the Cochran χ² based Q test followed by subsidiary analysis or by random-effects regression models with restricted maximum likelihood estimation [17,18]. Sources of heterogeneity were investigated by stratified meta-analyses based on ethnicity, and ER status. Ethnic group was defined as East Asians (i.e., Chinese, Japanese, and Korean), Caucasians (i.e. people of European origin), Africans and other ethnic populations. In addition, ethnicity, sample size, age at test and genotyping method was analyzed as covariates in meta-regression. The significance of the pooled OR was determined by Z test. Publication bias was assessed with the Egger test and Begg test [19,20]. Sensitivity analysis was performed by removing each individual study in turn from the total and re-analyzing the remainder. Power analysis was calculated with the pooled OR estimate from different ethnicity and allele frequency in controls.

The analysis was conducted using the Stata software version 10.0 (Stata Corporation, College Station, TX). All the P-values were for two-sided analysis and values of P<0.05 were considered statistically significant.

Results

Study Characteristics

The combined search yielded 109 references. Figure S1 shows the study selection process. Finally, a total of 24 eligible association studies with 131,983 BC cases and 200,314 controls were identified [9,15,16,21–41], with 10 studies genotyping more than one variant. The main study characteristics were summarized in Table 1. There are 31 data sets from 15 studies with 85,279 BC cases and 144,552 controls concerning rs10941679 and 32 data sets from 14 studies involving 40,446 BC cases and 78,492 controls concerning rs4415084. For the rs981782 polymorphism, 17 data sets from 7 studies involved a total of 44,609 BC cases and 78,192 controls. These three polymorphisms were found to occur in frequencies consistent with HWE in the control populations of the all published studies. Statistical power to detect risk allele is 96%, 92% and 90% for rs10941679, rs4415084 and rs981782 polymorphism, respectively.

Association of rs10941679 Polymorphism with Breast Cancer

Overall, there was evidence of an association between the increased risk of BC and the variant in different genetic models when all the eligible studies were pooled into the meta-analysis (Figure S2). Using random effect model, significantly increased risks were found among Caucasian populations (G allele: OR = 1.08, 95% CI: 1.05–1.12, P<10⁻⁵; heterozygous: OR = 1.10, 95% CI: 1.06–1.15, P<10⁻⁵; homozygote: OR = 1.12, 95% CI: 1.05–1.20, P<10⁻⁵). Similar significant associations were also observed for East Asians with per-allele OR of 1.05 (95% CI: 1.01–1.09, P = 0.01). However, no significant association was found for African and other ethnic populations in all genetic models (Table 2).

Furthermore, we performed case–control analyses by subgroups according to estrogen receptor status. A stronger association was observed for the polymorphism with ER-positive tumors [per-allele OR = 1.16, 95% CI: 1.11–1.21; P(Z) = 0.02] versus ER-negative tumors [per-allele OR = 1.02, 95% CI: 0.99–1.05; P(Z) = 0.21; P(Q) = 0.49] (Figure 1).

Significant heterogeneity was present among the 33 data sets (P<0.05). In meta-regression analysis, sample size (P = 0.13), genotyping method (P = 0.37), mean age of cases (P = 0.25) and controls (P = 0.61), did not significantly explained such heterogeneity. By contrast, ethnicity (P = 0.001) was significantly correlated with the magnitude of the genetic effect.

Association of rs4415084 Polymorphism with Breast Cancer

Significant heterogeneity was present among the included studies of the rs4415084 polymorphism (P<0.05). Ethnicity (P = 0.007) and sample size (P = 0.03) explained a large part of the heterogeneity, whereas genotyping method (P = 0.58), mean age of cases (P = 0.18) and controls (P = 0.32) explained little heterogeneity. In the overall analysis, the rs4415084 polymorphism on chromosome 5p12 was significantly associated with elevated BC risk for Caucasians with a per-allele OR of 1.10 (95% CI: 1.06–1.14, P<10⁻⁵; Figure S3). Significant associations were also found for heterozygous (OR = 1.08, 95% CI: 1.01–1.16, P = 0.03) and homozygote (OR = 1.18, 95% CI: 1.07–1.31,
Significant associations were also detected among East Asian populations with per-allele OR of 1.08 (95% CI: 1.03–1.14, \( P = 0.004 \)), while no significant associations were detect for African and other ethnic populations in all genetic models (Table 3). To investigate whether the polymorphism were associated with particular forms of breast cancer, we analyzed the associations between rs4415084 and breast cancer risk by ER status. The polymorphism was statistically significantly associated with greater risk of ER+ breast cancer [per-allele OR = 1.14, 95% CI: 1.09–1.20; \( P(Z) = 10^{-2} \); \( P(Q) = 0.004 \)] than ER- breast cancer [per-allele OR = 1.00, 95% CI: 0.95–1.06; \( P(Z) = 0.96 \); \( P(Q) = 0.65 \)] (Figure 2).

Table 1. Characteristics of the studies included in the meta-analysis.

| Study          | Year | Ethnicity               | Genotyping method | No. of cases/controls | Control source |
|----------------|------|-------------------------|-------------------|-----------------------|---------------|
| Easton [9]     | 2007 | European, America, Australian | SNP Array, TaqMan | 15335/17802          | GP            |
| Stacey [15]    | 2008 | European                | SNP Array         | 5028/32090           | GP            |
| Thomas [16]    | 2009 | American, European      | SNP Array, TaqMan | 7849/9835            | GP            |
| Mcinerney [21] | 2009 | Irish                   | KASPar             | 882/997              | GP            |
| Zheng [22]     | 2009 | African American        | Massarray         | 810/1784             | GP            |
| Ruiz-Narvaez [23] | 2010 | African American        | iPLEX             | 886/1089             | GP            |
| Antoniou [24]  | 2010 | European, America       | iPLEX             | 8534/7011            | GP            |
| Bhatti [25]    | 2010 | American                | TaqMan            | 776/997              | GP            |
| Reeves [26]    | 2010 | British                 | TaqMan            | 10306/10393          | GP            |
| Zheng [27]     | 2010 | Chinese                 | SNP Array         | 3039/3082            | GP            |
| Barnholtz-Sloan [28] | 2010 | American               | GoldenGate        | 1971/1775           | GP            |
| Wang [29]      | 2010 | European, American      | SNP Array         | 3030/2427            | GP            |
| Teraoka [30]   | 2011 | Dane, American          | Golden Gate       | 704/1387             | GP            |
| Fletcher [31]  | 2011 | British                 | SNP Array, GoldenGate | 7643/7443   | GP            |
| Campa [32]     | 2011 | American, European      | TaqMan            | 6396/9225           | GP            |
| Milne [33]     | 2011 | European, North America, Australian, Asian | TaqMan | 45377/74253 | GP |
| Li [34]        | 2011 | European                | SNP Array         | 1557/4584            | GP            |
| Kim [35]       | 2012 | Korean                  | SNP Array, TaqMan | 2257/2052            | GP            |
| Huo [36]       | 2012 | Nigerian                | GoldenGate        | 1509/1383            | GP            |
| Chan [37]      | 2012 | Chinese                 | TaqMan            | 1175/1499            | GP            |
| Sueta [38]     | 2012 | Japanese                | TaqMan            | 697/1394             | HP            |
| Liu [39]       | 2012 | Chinese                 | TaqMan            | 846/882              | GP            |
| Harlid [40]    | 2012 | European                | MassARRAY         | 3584/5063            | GP            |
| Dai [41]       | 2012 | Chinese                 | TaqMan            | 1792/1867            | GP            |

GP: general population, HP: hospital patient.

doi:10.1371/journal.pone.0072154.t001

Table 2. Meta-analysis of the 5p12 rs10941679 polymorphism on breast cancer risk.

| Sub-group analysis | No. of data sets | No. of cases/controls G allele | G allele | Heterozygous | Homozygous |
|--------------------|------------------|--------------------------------|----------|-------------|-----------|
|                    |                  |                                | OR (95%CI) | P(Z) | P(Q) | OR (95%CI) | P(Z) | P(Q) | OR (95%CI) | P(Z) | P(Q) |
| Ethnicity          |                  |                                |          |      |      |           |      |      |            |      |      |
| Caucasian          | 18               | 70103/127620                  | 1.10 (1.06–1.15) | \(<10^{-5}\) & \(<10^{-4}\) | 1.11 (1.05–1.16) | \(<10^{-3}\) & 0.002 | 1.15 (1.03–1.28) | 0.01 | \(<10^{-4}\) |
| East Asian         | 7                | 11093/11588                   | 1.05 (1.01–1.09) | 0.01 & 0.63 | 1.05 (0.98–1.12) | 0.20 & 0.59 | 1.09 (1.02–1.18) | 0.01 | 0.87 |
| African            | 4                | 3569/4658                     | 1.01 (0.93–1.10) | 0.81 & 0.37 | 1.12 (0.92–1.35) | 0.27 & 0.001 | 1.01 (0.76–1.33) | 0.95 | 0.93 |
| Other              | 2                | 514/686                       | 1.18 (0.99–1.40) | 0.07 & 0.51 | 1.20 (0.93–1.56) | 0.17 & 0.70 | 1.45 (1.01–2.09) | 0.05 | 0.36 |

\(^a\)Cochran’s chi-square Q statistic test used to assess the heterogeneity in subgroups.
\(^b\)Cochran’s chi-square Q statistic test used to assess the heterogeneity between subgroups.

doi:10.1371/journal.pone.0072154.t002
Association of rs981782 Polymorphism with Breast Cancer

For Caucasian populations, the overall per-allele OR of the T variant for breast cancer was 1.05 (95% CI: 1.02–1.07, P = 0.001; Figure S4), with corresponding results for heterozygous and homozygous of 1.03 (95% CI: 0.98–1.07, P = 0.24) and 1.07 (95% CI: 0.98–1.17, P = 0.12), respectively. However, no significant associations were detected among African in all comparisons (Table 4). No significant between-study heterogeneity was detected for the vast majority of comparisons (Table 4).

Discussion

The association between polymorphisms of 5p12 and breast cancer risk had been originally reported by Easton et al [9]. However, the accurate relationship of 5p12 common polymorphisms with breast cancer risk for different ethnic populations was still unknown due to the inconsistent findings [21,23,27–30,35–37]. This is the first comprehensive meta-analysis, which comprise a total of 131,983 BC cases and 200,314 controls from 24 case–control studies, examining the association of three commonly studied polymorphisms of 5p12 (rs10941679, rs4415084, and rs981782) with breast cancer risk. Our results demonstrated that rs10941679-G allele, rs4415084-T allele and rs981782-T allele is a
risk factor for developing breast cancer. Replication of initial genome-wide association findings is considered a gold standard for reporting genotype–phenotype associations. The results from the Michailidou et al. [42] and Zheng et al. [43] study of rs10941679 reporting genotype–phenotype associations. The results from the genome-wide association findings is considered a gold standard for, among Caucasians and East Asians and between different races, with a prevalence of more than 40% rs4415084, the distribution of the risk T allele varies extensively between African populations, with a prevalence of 25%, 51%, and 19%, the rs10941679 varies between Caucasians, East Asians, and other ethnic populations. Similar results were also observed for 5p12-rs981782. There are associations were found in African and other ethnic populations. However, no associations were found in Caucasians and East Asians for 5p12-regression. In the stratified analysis by ethnicity, significant between-study heterogeneity by subgroup analysis and meta-

| Sub-group analysis | No. of data sets | No. of cases/controls | T allele | Heterozygous | Homozygous |
|--------------------|------------------|-----------------------|----------|-------------|-----------|
| Ethnicity          |                  |                       |          |             |           |
| Caucasian          | 22               | 30587/64012           | 1.10 (1.06–1.14) | 0.03 | 0.15 |
| East Asian         | 5                | 6560/6805             | 1.08 (1.03–1.14) | 0.03 | 0.01 |
| African            | 3                | 2790/2901             | 1.00 (0.87–1.14) | 0.03 | 0.01 |
| Other              | 2                | 509/685               | 1.12 (0.94–1.33) | 0.03 | 0.01 |

* Cochran’s chi-square Q statistic test used to assess the heterogeneity in subgroups.

Because ER status is one of the major markers of breast cancer subtypes, we further performed analyses to test for differences in the associations of these polymorphisms with breast cancer risk with respect to different ER status. The findings that 5p12-rs10941679 and 5p12-rs4415084 largely affect ER-positive disease are confirmed by our meta-analysis of all available data. The pooled OR estimate is consistent with little or no effect of the two SNPs on ER-negative disease. These findings provide further support for the notion that ER-negative and ER-positive tumors result from different etiologic pathways, rather than different stages of tumor evolution within a common carcinogenic pathway [45]. The magnitude of the observed differences is small, and by themselves these findings are unlikely to have any immediate clinical implications. However, the observed differences provide clues to the biological mechanisms that underpin tumor heterogeneity, which may ultimately lead to improved treatment and prevention.

Large sample and unbiased epidemiological studies of predisposition genes polymorphisms could provide insight into the in vivo relationship between candidate genes and complex diseases. Nevertheless, small sample sized association studies lack statistical power and have resulted in apparently contradicting results. The interpretation of these studies has been further complicated by the use of different ethnic populations and phenotypic heterogeneity. An alternative therefore is to pool data from a range of studies via meta-analysis, thus enhancing the statistical power of the analysis for the estimation of genetic effects. The familial excess in risk not accounted for by BRCA1 or BRCA2 is plausibly explained by a polygenic model in which a large number of “low-penetrance” variants act in combination to cause wide variation in risk in the population [46]. Recently, several “low-penetrance” variants have been identified through meta-

These findings greatly contribute to the understanding of the genetic as well as the pathological basis of the development of breast cancers.

Several potential limitations of the present meta-analysis should be taken into consideration. Firstly, the subgroup meta-analyses dealing with interactions between the 5p12 polymorphisms and Africans or other ethnic populations are based on the small number of studies where such information is available. As studies among the African or other ethnic populations are currently limited, further studies including a wider spectrum of subjects

Table 3. Meta-analysis of the 5p12 rs4415084 polymorphism on breast cancer risk.

- **OR (95%CI)**: Odds Ratio (95% Confidence Interval)
- **P(Z)**: Statistical significance
- **P(Q)**: Heterogeneity across studies

| Sub-group analysis | No. of data sets | No. of cases/controls | T allele | Heterozygous | Homozygous |
|--------------------|------------------|-----------------------|----------|-------------|-----------|
| Ethnicity          |                  |                       |          |             |           |
| Caucasian          | 22               | 30587/64012           | 1.10 (1.06–1.14) | 0.03 | 0.15 |
| East Asian         | 5                | 6560/6805             | 1.08 (1.03–1.14) | 0.03 | 0.01 |
| African            | 3                | 2790/2901             | 1.00 (0.87–1.14) | 0.03 | 0.01 |
| Other              | 2                | 509/685               | 1.12 (0.94–1.33) | 0.03 | 0.01 |

* Cochran’s chi-square Q statistic test used to assess the heterogeneity in subgroups.

Other population. Thus, failing to identify any significant association in Africans and other populations could be due to substantially lower statistical power caused by the relatively lower prevalence of T allele. Therefore, additional studies are warranted to further validate ethnic difference in the effect of these polymorphisms on breast cancer risk. Secondly, study design or small sample size or some environmental factors may affect the results. Most of these studies did not consider most of the important environmental factors. It is possible that variation at this locus has modest effects on breast cancer, but environmental factors may predominate in the progress of breast cancer, and mask the effects of this variation. Specific environmental factors like lifestyle and hormone use that have been already well studied in recent decades [3]. In addition, different populations usually have different linkage disequilibrium patterns. A polymorphism may be in close linkage with another nearby causal variant in one ethnic population but not in another. These polymorphisms may be in close linkage with different nearby causal variants in different populations.

Table 3. Meta-analysis of the 5p12 rs4415084 polymorphism on breast cancer risk.

| Sub-group analysis | No. of data sets | No. of cases/controls | T allele | Heterozygous | Homozygous |
|--------------------|------------------|-----------------------|----------|-------------|-----------|
| Ethnicity          |                  |                       |          |             |           |
| Caucasian          | 22               | 30587/64012           | 1.10 (1.06–1.14) | 0.03 | 0.15 |
| East Asian         | 5                | 6560/6805             | 1.08 (1.03–1.14) | 0.03 | 0.01 |
| African            | 3                | 2790/2901             | 1.00 (0.87–1.14) | 0.03 | 0.01 |
| Other              | 2                | 509/685               | 1.12 (0.94–1.33) | 0.03 | 0.01 |

* Cochran’s chi-square Q statistic test used to assess the heterogeneity in subgroups.

| No. of | OR (95%CI) | P(Z) | P(Q) |
|--------|------------|------|------|
| Cases  |            |      |      |
| 22     | 1.10 (1.06–1.14) | <10^{-5} | <10^{-4} |
| 5      | 1.08 (1.03–1.14) | 0.01 | 0.002 |
| 3      | 1.00 (0.87–1.14) | 0.05 | 0.004 |
| 2      | 1.12 (0.94–1.33) | 0.02 | 0.01 |

- OR: Odds Ratio
- CI: Confidence Interval
- P: Statistical significance
- Q: Heterogeneity across studies

because of the use of different ethnic populations and phenotypic heterogeneity. An alternative therefore is to pool data from a range of studies via meta-analysis, thus enhancing the statistical power of the analysis for the estimation of genetic effects. The familial excess in risk not accounted for by BRCA1 or BRCA2 is plausibly explained by a polygenic model in which a large number of “low-penetrance” variants act in combination to cause wide variation in risk in the population [46]. Recently, several “low-penetrance” variants have been identified through meta-

These studies greatly contribute to the understanding of the genetic as well as the pathological basis of the development of breast cancers.

Several potential limitations of the present meta-analysis should be taken into consideration. Firstly, the subgroup meta-analyses dealing with interactions between the 5p12 polymorphisms and Africans or other ethnic populations are based on the small number of studies where such information is available. As studies among the African or other ethnic populations are currently limited, further studies including a wider spectrum of subjects

Table 3. Meta-analysis of the 5p12 rs4415084 polymorphism on breast cancer risk.

| Sub-group analysis | No. of data sets | No. of cases/controls | T allele | Heterozygous | Homozygous |
|--------------------|------------------|-----------------------|----------|-------------|-----------|
| Ethnicity          |                  |                       |          |             |           |
| Caucasian          | 22               | 30587/64012           | 1.10 (1.06–1.14) | 0.03 | 0.15 |
| East Asian         | 5                | 6560/6805             | 1.08 (1.03–1.14) | 0.03 | 0.01 |
| African            | 3                | 2790/2901             | 1.00 (0.87–1.14) | 0.03 | 0.01 |
| Other              | 2                | 509/685               | 1.12 (0.94–1.33) | 0.03 | 0.01 |

* Cochran’s chi-square Q statistic test used to assess the heterogeneity in subgroups.

| No. of | OR (95%CI) | P(Z) | P(Q) |
|--------|------------|------|------|
| Cases  |            |      |      |
| 22     | 1.10 (1.06–1.14) | <10^{-5} | <10^{-4} |
| 5      | 1.08 (1.03–1.14) | 0.01 | 0.002 |
| 3      | 1.00 (0.87–1.14) | 0.05 | 0.004 |
| 2      | 1.12 (0.94–1.33) | 0.02 | 0.01 |

- OR: Odds Ratio
- CI: Confidence Interval
- P: Statistical significance
- Q: Heterogeneity across studies
**Figure 2.** Association between 5p12 rs4415084 and breast cancer risk by ER status.
doi:10.1371/journal.pone.0072154.g002

**Table 4.** Meta-analysis of the 5p12 rs981782 polymorphism on breast cancer risk.

| Sub-group analysis | No. of data sets | No. of cases/controls | T allele | Heterozygous | Homozygous |
|--------------------|------------------|-----------------------|----------|--------------|------------|
|                    |                  |                       | OR (95%CI) | P(Z) | P(Q) | OR (95%CI) | P(Z) | P(Q) | OR (95%CI) | P(Z) | P(Q) |
| Ethnicity          |                  |                       | NA       | NA | NA | NA       | NA | NA | NA       | NA | NA |
| Caucasian          | 16               | 43868/77535           | 1.05 (1.02–1.07) | 0.001 | 0.08 | 1.03 (0.98–1.07) | 0.24 | 0.43 | 1.07 (0.98–1.17) | 0.12 | 0.04 |
| African            | 1                | 741/657               | 1.11 (0.86–1.44) | 0.43 | NA | 0.61 (0.23–1.63) | 0.32 | NA | 0.74 (0.28–1.91) | 0.53 | NA |

NA: not available.

*a*Cochran's chi-square Q statistic test used to assess the heterogeneity in subgroups.

*b*Cochran's chi-square Q statistic test used to assess the heterogeneity between subgroups.

doi:10.1371/journal.pone.0072154.t004
should be carried to investigate the role of these variants in different populations. Secondly, our results were based on unadjusted estimates, while a more precise analysis should be conducted if all individual raw data were available, which would allow for the adjustment by other co-variants including age, cigarette consumption, alcohol drinking, menopausal status, and other lifestyle. Thirdly, the single locus-based nature of meta-analysis precluded the possibility of gene-gene and gene-environment interactions, as well as haplotype-based effects, suggesting that additional studies assessing these aspects are necessary.

In summary, findings from this meta-analysis indicate that 5p12 rs10941679, rs4415084, and rs981782 polymorphism is significantly associated with an increased risk of breast cancer, particularly in Caucasian and East Asian populations. More work is needed to further investigate the association of these polymorphisms across different histological types or tumor staging of breast cancer. Besides, future studies are recommended to identify the possible gene-gene and gene-environmental interactions in this association.

Supporting Information

Figure S1  Study selection process.  (TIF)

Figure S2  Forest plot from the meta-analysis of breast cancer risk and 5p12 rs10941679 polymorphism.  (TIF)

References

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) CA Cancer J Clin 55: 74–108.
2. Porter P (2008) “Westernizing” women’s risks? Breast cancer in lower-income countries. N Engl J Med 358: 213–6.
3. McPherson K, Steel CM, Dixon JM (2000) ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ 321: 624–6.
4. Nathanson KL, Wooster R, Weber BL (2001) Breast cancer genetics: what we know and what we need. Nat Med 7: 552–6.
5. Balmann A, Gray J, Ponder B (2003) The genetics and genomics of cancer. Nat Genet 33(suppl): 230–44.
6. Walsh T, Gasade S, Coats KH, Swisher E, Stray SM, et al. (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295: 1379–88.
7. Antoniou AC, Easton DF (2006) Models of genetic susceptibility to breast cancer. Oncogene 25: 5089–95.
8. Antoniou AC, Pharoah PD, McManus G, Day NE, Stratton MR, et al. (2002) A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 86: 76–83.
9. Easton DF, Pooley KA, Dunn AM, Pharoah PD, Thompson D, et al. (2007) Genotype-wide association study identifies novel breast cancer susceptibility loci. Nature 447: 1087–93.
10. Ahmed S, Thomas G, Ghousainai M, Healey CS, Humphreys MK, et al. (2009) Newly discovered breast cancer susceptibility loci on 1p34 and 17q23.2. Nat Genet 41: 585–90.
11. Turnbull C, Ahmed S, Morrison J, Perner D, Renwick A, et al. (2010) Genotype-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 42: 504–7.
12. Hiddord LA, Sehupathy P, Junkins HA, Ramos EM, Mehta JP, et al. (2009) Potential etiologic and functional implications of genome wide association loci for human diseases and traits. Proc Natl Acad Sci USA 106: 9362–7.
13. Stacey SN, Manolescu A, Sulen P, Rudnai P, Gudmundsson J, et al. (2007) Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 39: 865–9.
14. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, et al. (2007) A genome-wide association study identifies alleles in FGF2R2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 39: 870–4.
15. Stacey SN, Manolescu A, Sulen P, Thorlacius S, Gudjonsson SA, et al. (2008) Common variants on chromosome 5p12 confeder susceptibility to estrogen receptor-positive breast cancer. Nat Genet 40: 703–6.
16. Thomas G, Jacobs KB, Kraft P, Yeager M, Wacholder S, et al. (2009) A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet 41: 579–84.
17. Deebmanian R, Laid N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–88.
18. Thompson SG, Sharp SJ (1999) Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 18: 2693–708.
19. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–34.
20. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088–101.
21. McKenney N, Colleran G, Rowan A, Waller A, Barclay E, et al. (2009) Low penetrance breast cancer predisposition SNPs are site specific. Breast Cancer Res Treat 117: 151–9.
22. Zheng W, Cai Q, Signorell LB, Long J, Hargreaves MK, et al. (2009) Evaluation of 11 breast cancer susceptibility loci in African-American women. Cancer Epidemiol Biomarkers Prev 18: 2761–4.
23. Ruiz-Narvaez EA, Rosenberg I, Rotimi CN, Cupples LA, Boggs DA, et al. (2010) Genetic variants on chromosome 5p12 are associated with risk of breast cancer in African American women: the Black Women’s Health Study. Breast Cancer Res Treat 121: 525–30.
24. Antoniou AC, Belsey J, McGuiggan L, Sinilnikova OM, Healey S, et al. (2010) Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res 70: 9742–54.
25. Bhatti P, Doody MM, Rajaraman P, Alexander BH, Yeager M, et al. (2010) Novel breast cancer risk alleles and interaction with ionizing radiation among U.S. Radiologic Technologists. Radiat Res 173: 214–24.
26. Reeves GK, Travis RC, Green J, Bull D, Tippier S, et al. (2010) Incidence of breast cancer and its subtypes in relation to individual and multiple low-penetrate genetic susceptibility loci. JAMA 304: 426–34.
27. Zheng W, Wen W, Gao YT, Shyr Y, Zheng Y, et al. (2010) Genetic and clinical predictors for breast cancer risk assessment and stratification among Chinese women. J Natl Cancer Inst 102: 972–81.
28. Barnholtz-Sloan JS, Shetty PB, Guan X, Nyante SJ, Luo J, et al. (2010) FGFR2 and other loci identified in genome-wide association studies are associated with breast cancer in African-American and younger women. Carcinogenesis 31: 1417–23.
29. Wang X, Pankratz VS, Frederiksen Z, Tarrell R, Karasu M, et al. (2010) Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 19: 2388–97.
30. Teraoka SN, Bernstein JL, Reiner AS, Haile RW, Bernstein L, et al. (2011) Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women’s Environment, Cancer, and Radiation Epidemiology (WECARE) Study. Breast Cancer Res 13: R114.
31. Fletcher O, Johnson N, Orr N, Hosking FJ, Gibson LJ, et al. (2011) Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. J Natl Cancer Inst 103: 425–33.
32. Campo D, Kaaks R, Le Marchand L, Haiman CA, Travis RC, et al. (2011) Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium. J Natl Cancer Inst 103: 1252–63.

Figure S3  Forest plot from the meta-analysis of breast cancer risk and 5p12 rs4415084 polymorphism.  (TIF)

Figure S4  Forest plot from the meta-analysis of breast cancer risk and 5p12 rs981782 polymorphism.  (TIF)

Figure S5  Begg’s funnel plot for publication bias in studies on 5p12-rs10941679 polymorphism and breast cancer.  (TIF)

Figure S6  Begg’s funnel plot for publication bias in studies on 5p12-rs4415084 polymorphism and breast cancer.  (TIF)

Figure S7  Begg’s funnel plot for publication bias in studies on 5p12-rs981782 polymorphism and breast cancer.  (TIF)

Checklist S1  (DOC)

Author Contributions

Conceived and designed the experiments: YMY ZGC. Performed the experiments: YMY ZGC. Analyzed the data: YMY ZGC. Contributed reagents/materials/analysis tools: YMY ZGC. Wrote the paper: YMY ZGC HW YZ.
33. Milne RL, Goode EL, García-Closas M, Couch FJ, Severi G, et al. (2011) Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer. Cancer Epidemiol Biomarkers Prev 20: 2222–31.
34. Li J, Humphreys K, Heikkinen T, Antonäkki K, Blomqvist C, et al. (2011) A combined analysis of genome-wide association studies in breast cancer. Breast Cancer Res Treat 126: 717–27.
35. Kim HC, Lee JY, Sung H, Choi JY, Park SK, et al. (2012) A genome-wide association study identifies a breast cancer risk variant in ERBB4 at 2q34: results from the Seoul Breast Cancer Study. Breast Cancer Res 14: R56.
36. Hao D, Zheng Y, Ogundiran TO, Adebamowo C, Nathanson KL, et al. (2012) Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. Carcinogenesis 33: 833–40.
37. Chan M, Ji SM, Liaw CS, Yap VS, Law HY, et al. (2012) Association of common genetic variants with breast cancer risk and clinicopathological characteristics in a Chinese population. Breast Cancer Res Treat 136: 209–20.
38. Sueta A, Ito H, Kawase T, Hirose K, Hosono S, et al. (2012) A genetic risk predictor for breast cancer using a combination of low-penetrance polymorphisms in a Japanese population. Breast Cancer Res Treat 132: 711–21.
39. Liu X, Qin Z, Shen H, Xue J, Jiang Y, et al. (2012) Genetic variants at 5p12 and risk of breast cancer in Han Chinese. J Hum Genet 57: 638–41.
40. Harlid S, Ivarsson MI, Butt S, Grybowski E, Eyfjörd JE, et al. (2012) Combined effect of low-penetrant SNPs on breast cancer risk. Br J Cancer 106: 309–96.
41. Dai J, Hu Z, Jiang Y, Shen H, Dong J, et al. (2012) Breast cancer risk assessment with five independent genetic variants and two risk factors in Chinese women. Breast Cancer Res 14: R17.
42. Michailidou K, Hall P, Gonzalez-Neira A, Ghousaini M, Dennis J, et al. (2013) Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 45: 353–61.
43. Zhong W, Zhang B, Cai Q, Sung H, Michailidou K, et al. (2013) Common genetic determinants of breast-cancer risk in East Asian women: a collaborative study of 23 637 breast cancer cases and 25 579 controls. Hum Mol Genet 22: 2539–50.
44. Hemminki K, Lorenzo Bermejo J, Forsti A (2006) The balance between heritable and environmental aetiology of human disease. Nat Rev Genet 7: 958–65.
45. Collaborative Group on Hormonal Factors in Breast Cancer (2002) Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 360: 187–95.
46. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, et al. (2002) Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31: 33–36.
47. Wang H, Yang Z, Zhang H (2013) Assessing interactions between the associations of fibroblast growth factor receptor 2 common genetic variants and hormone receptor status with breast cancer risk. Breast Cancer Res Treat 137: 511–22.
48. Liu L, Yuan P, Liu L, Wu C, Zhang X, et al. (2011) A functional −77T>C polymorphism in XRCC1 is associated with risk of breast cancer. Breast Cancer Res Treat 125: 479–87.
49. Chen W, Zhong R, Ming J, Zou L, Zhu B, et al. (2012) The SLC4A7 variant rs4973576 is associated with breast cancer risk: evidence from a case-control study and a meta-analysis. Breast Cancer Res Treat 136: 847–57.